NOT ALL PAST SUCCESSES IN CANCER RESEARCH NOT ALL PAST SUCCESSES IN CANCER RESEARCH HAVE BEEN FOLLOWED BY ACTIONSHAVE BEEN FOLLOWED BY ACTIONS
EUROCHIP-2EUROCHIP-2 THE ACTIONTHE ACTION Project & newsProject & news
Public Health ProgramEUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE - GENERAL
www.tumori.net/eurochip
WHAT IS THE EUROCHIP-2 THE ACTION PROJECT?WHAT IS THE EUROCHIP-2 THE ACTION PROJECT?
• It is a translational research project (from epidemiology to public health)
• It is a project against disparities
• It is an EC project
• It aims to research ways to promote health by EU imprimatur
• Its goal is to promote public health actions against cancer in each EU country
• It works in the building of an European platform for cancer control
EUROPE WITHIN THE WORLDEUROPE WITHIN THE WORLDAGE-STANDARDIZED INCIDENCE RATES
Source: GLOBOCAN 2002, IARC. Age-Standardised (World) rates, per 100,000
EUROPE WITHIN THE WORLDEUROPE WITHIN THE WORLD
Source: GLOBOCAN 2002, IARC. Age-Standardised (World) rates, per 100,000
AGE-STANDARDIZED MORTALITY RATES
All cancers combined: Europe5-year age-adj. relative survival trend in male
8.5
7.5
10.5
6.7
12.1
6.6
8.9
8.8
6.3
7.9
9.2
8.7
4.5
7.2
5.2
3.5
6.6
-2.31.8
0 10 20 30 40 50 60
Iceland
Sweden
Swiss
Dutch
French
German
Norway
Finland
Spanish
Europe
Italian
English
Denmark
Wales
Scotland
Slovenia
Estonia
Slovakia
Polish
Relative survival
1984
1993-1984
8.0
6.5
5.2
9.5
6.4
4.5
4.7
7.4
7.5
7.5
6.4
3.9
4.5
4.0
6.8
7.3
6.3
3.9
0 10 20 30 40 50 60
French
Swiss
Sweden
Dutch
Spanish
German
Finland
Iceland
Norvay
Italian
Europe
English
Slovenia
Wales
Scotland
Slovakia
Estonia
Polish
Relative survival
1984
1993-1984
5-year age-adj. relative survival trend in female
Differences in Europe. Relative risks (Max/Min). All cancers combined
Year Males Females
Mortality1985 2.3 1.8
1996 4.3 1.9
Incidence1985 1.9 1.9
1996 1.9 2.2
5-yrs Survival1985-89 2.2 2.0
1990-94 2.5 2.0
Sources: EUROCIM - EUROCARE
Data from cancer registries of these countries
Austria, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Disks are proportional to the national health expenditure ($ PPP)
$ PPP: Parity Purchasing Power per capita (US $) Sourcesi: OECD 2002 and EUROCARE-3
GDP (1997) and 5-year cancer survival
INDICATOR AINDICATOR BINDICATOR C...INDICATOR Z
INDICATOR AINDICATOR BINDICATOR C...INDICATOR Z
INFORMATION
ANALYSIS
ACTIONS
GENERAL AIMS OF EUROCHIP-2GENERAL AIMS OF EUROCHIP-2
1. To extend the collaboration
2. To promote national groups in each country
3. To analyse the behaviour of available indicators
4. To discuss on deficiencies at national and international level
5. To promote at least one important ACTION in each country
EUROCHIP-2 DISCUSSION PLANEUROCHIP-2 DISCUSSION PLAN
COUNTRY 1 COUNTRY 2 COUNTRY 3 COUNTRY 30
ACTION 1
ACTION 2
ACTION 3
ACTION 3
ACTION 4
ACTION 4
ACTION 5
ACTION 6
ACTION 6
EUROPEAN PUBLIC HEALTH ACTION –
early diagnosis
Cervical screening
EUROPEAN PUBLIC HEALTH ACTION –
care & treatment
Pilot studies
EUROPEAN PUBLIC HEALTH ACTION -
prevention
Dietary prevention
EU CANCER PLAN
UTERUS CANCER STANDARDIZED MORTALITY RATEAGE: 20 – 44 (IN THESE AGES MOSTLY CERVICAL CANCER)
European standard per 100,000
htt
p:/
/ep
ica
nce
r.is
s.it
PILLA
R 1EARLY
DIAGNOSIS
- Describe the opportunistic/programmed cervical cancer screening in those countries at present time
- For countries without cervical screening programs: find difficulties and problems with specific assessment studies in these Eastern European countries
- For countries with cervical screening programs: to help specific activities that at the moment are not subsidize
- To create relations with groups of pressure with national health ministries and with European Parliament
- To share information with other networks (EUNICE, European Cancer Screening networks)
EUROCHIP-2 ACTION:TASK FORCE ON CERVICAL CANCER SCREENING
AIMSACTION 1
ASSESSMENT PHASES: ASSESSMENT PHASES: COLLECTION OF INFO ONCOLLECTION OF INFO ON
• Use of Policies, Guidelines, and Norms
• Program Management Issues
• Health Services
• Information and Education Activities
• Community Perspectives
• Laboratory
• Information Systems
ROMANIA
ROMANIA
Screening prices Screening prices VS VS
treatment pricestreatment prices• In Bulgaria the mean value of programme screening for 1
person is around 5 €
• Target population: 1.8 million (age 25-60)
• Screening interval: 3 years
• 5 € * 0.6 million = 3 million € per year
V.
Zla
tko
v -
Bu
lgar
ia (
2006
)
BULGARIA
BULGARIA
Cervical cancerstages
Number of cases in Bulgaria (2001)
Prices according to EU data(Andrae Bengt - 2004)
Per item Total
St. III – IV 347 30 000 € 10 410 000 €
St. I – II 670 9 000 € 6 030 000 €
CIS 275 300 € 83 500 €
Total 1292 - 16 522 500 €
BULGARIAN BULGARIAN ESTIMATESESTIMATES
ESTONIA
ESTONIA PROBLEMS OF THE ORGANISED PROBLEMS OF THE ORGANISED SCREENING PROGRAMSCREENING PROGRAM
P. Veerus - Estonia (2006)
• Low participation: Only 21.7% of the 12,960 invited women attended the screening
• No funds for screening registry
• No invitation of women without insurance (~5% of population)
• To use experience from other countries to produce successful campaigns
• Group of pressure for invitation of women without insurance
• Money for starting the organization of screening registry
EUROCHIP FUNDEUROCHIP FUND
1.Budget: 17.500 € - Only for personnel costs
2. Involvement of personnel for ACTIONS
3.Money sent:
• Directly to personnel OR
• To Institute involved in the project
4.Necessary admin. documentation (at the end of the work)
• Declaration of money receipt (by personnel)
• Declaration of personnel payment (by Institute)